Huadong Medicine Overview

  • Year Founded
  • 1993

Year Founded

  • Status
  • Public

  • Employees
  • 19,095

Employees

  • Stock Symbol
  • 000963

Stock Symbol

  • Investments
  • 14

  • Share Price
  • $3.73
  • (As of Friday Closing)

Huadong Medicine General Information

Description

Huadong Medicine Co Ltd is engaged in the production and sales of antibiotics, proprietary Chinese medicine, chemical synthetic medicine, and genetic engineering drug products. The company mainly operates its business through three segments. The Manufacturing Business segment is engaged in the research and development, production, and marketing of specialized medicines, medicines for chronic diseases, as well as special medicines. The Commercial Business segment is engaged in the sales of medicines, medical devices, ginseng, and antler pieces. The International Medical Beauty Business segment is engaged in the production and sales of regeneration products, hyaluronic acids, and botulinum toxin products.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • Number 858
  • Mogan Shan Road
  • Hangzhou, Zhejiang 310011
  • China
+86 0571
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Stock Exchange
SHE
Corporate Office
  • Number 858
  • Mogan Shan Road
  • Hangzhou, Zhejiang 310011
  • China
+86 0571

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Huadong Medicine Stock Performance

As of 20-Nov-2026, Huadong Medicine’s stock price is $3.73. Its current market cap is $6.54B with 1.75B shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.73 $3.81 $3.70 - $6.09 $6.54B 1.75B 15.3M $0.28

Huadong Medicine Financials Summary

As of 30-Sep-2026, Huadong Medicine has a trailing 12-month revenue of $6.38B.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 6,779,649 9,642,089 8,062,337 10,043,093
Revenue 6,378,783 6,064,535 5,840,142 5,741,975
EBITDA 580,103 702,233 718,205 607,744
Net Income 498,832 474,786 489,461 401,259
Total Assets 5,978,334 5,579,493 5,188,839 4,727,219
Total Debt 309,452 296,086 373,829 248,170
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Huadong Medicine Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Huadong Medicine‘s full profile, request access.

Request a free trial

Huadong Medicine Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Huadong Medicine Co Ltd is engaged in the production and sales of antibiotics, proprietary Chinese medicine, chemical sy
Pharmaceuticals
Hangzhou, China
19,095 As of 2025

London, United Kingdom
 

Basel, Switzerland
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Huadong Medicine Competitors (22)

One of Huadong Medicine’s 22 competitors is GSK, a Corporation company based in London, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
GSK Corporation London, United Kingdom
Roche Corporation Basel, Switzerland
Teva Pharmaceutical Industries Corporation Tel Aviv, Israel
Biocon Formerly PE-Backed Bengaluru, India
Aurobindo Pharma Corporation Hyderabad, India
You’re viewing 5 of 22 competitors. Get the full list »

Huadong Medicine Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Huadong Medicine Investments & Acquisitions (14)

Huadong Medicine’s most recent deal was a Later Stage VC with Ashvattha Therapeutics for . The deal was made on 13-Jan-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Ashvattha Therapeutics 13-Jan-2025 Later Stage VC Drug Discovery
Hengba Pharmaceutical 21-Jul-2024 Merger/Acquisition Pharmaceuticals
Chongqing Yuyan 14-Nov-2023 Early Stage VC Other Pharmaceuticals and Biotechnology
Jinannong Group 31-May-2023 Merger/Acquisition Other Agriculture
Huaren Technology 08-Aug-2022 Merger/Acquisition Other Pharmaceuticals and Biotechnology
You’re viewing 5 of 14 investments and acquisitions. Get the full list »

Huadong Medicine ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

30.89 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Huadong Medicine’s complete esg history, request access »

Huadong Medicine Exits (1)

Huadong Medicine’s most recent exit was on 09-Oct-2020 from Qyuns. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Qyuns 09-Oct-2020 Completed
To view Huadong Medicine’s complete exits history, request access »

Huadong Medicine Affiliates

Subsidiaries (8)

Name Industry Location Year Founded
Huachang Hi-Tech Anshan, China 2015
Doer Biologics Hangzhou, China 2014
Huaren Technology Wuhu, China 2006
Jinannong Group Nanjing, China 1996
Hengba Pharmaceutical Guiyang, China 1995
You’re viewing 5 of 8 affiliates. Get the full list.  »

Huadong Medicine FAQs

  • When was Huadong Medicine founded?

    Huadong Medicine was founded in 1993.

  • Where is Huadong Medicine headquartered?

    Huadong Medicine is headquartered in Hangzhou, China.

  • What is the size of Huadong Medicine?

    Huadong Medicine has 19,095 total employees.

  • What industry is Huadong Medicine in?

    Huadong Medicine’s primary industry is Pharmaceuticals.

  • Is Huadong Medicine a private or public company?

    Huadong Medicine is a Public company.

  • What is Huadong Medicine’s stock symbol?

    The ticker symbol for Huadong Medicine is 000963.

  • What is the current stock price of Huadong Medicine?

    As of 20-Nov-2026 the stock price of Huadong Medicine is $3.73.

  • What is the current market cap of Huadong Medicine?

    The current market capitalization of Huadong Medicine is $6.54B.

  • What is Huadong Medicine’s current revenue?

    The trailing twelve month revenue for Huadong Medicine is $6.38B.

  • Who are Huadong Medicine’s competitors?

    GSK, Roche, Teva Pharmaceutical Industries, Biocon, and Aurobindo Pharma are some of the 22 competitors of Huadong Medicine.

  • What is Huadong Medicine’s annual earnings per share (EPS)?

    Huadong Medicine’s EPS for 12 months was $0.28.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process